中医药联合化疗在非小细胞肺癌中的研究进展
Research Progress of Traditional Chinese Medicine Combined with Chemotherapy in Non-Small Cell Lung Cancer
DOI: 10.12677/ACM.2023.1391937, PDF,   
作者: 阿力木·依明, 马亚丽：新疆医科大学第四临床医学院，新疆 乌鲁木齐；马红霞*：新疆医科大学第四临床医学院自治区中医院，新疆 乌鲁木齐
关键词: 非小细胞肺癌；化疗；中医药；综述；Non-Small Cell Lung Cancer； Chemotherapy； Traditional Chinese Medicine； Review
摘要: 肺癌，从流行病上来看，无论是发病率还是死亡率，都是居于首要地位的恶性肿瘤之一，其中非小细胞肺癌(non-small cell lung cancer, NSCLC)占据肺癌比例80%之高，肺癌发现时大部分为晚期，患者避免不了遭受疼痛、咳嗽、气喘等肺部症状的折磨，生活质量大大降低。治疗方面，化疗仍是治疗肺癌的有效手段，近几年随着中医药的发展，其在协助治疗肺癌及改善化疗副作用方面有着一定的疗效，故本文对于目前临床中有关中医药联合化疗治疗非小细胞肺癌的研究进行综述。
Abstract: Epidemiologically, lung cancer is one of the most important malignant tumors in terms of morbidity and mortality, among which non-small cell lung cancer (NSCLC) accounts for 80% of lung cancer, most of which are found in advanced stage. Patients cannot avoid suffering from pain, cough, wheezing and other lung symptoms, and their quality of life is greatly reduced. In terms of treat-ment, chemotherapy is still an effective means to treat lung cancer. In recent years, with the devel-opment of traditional Chinese medicine, it has a certain effect in assisting the treatment of lung cancer and improving the side effects of chemotherapy. Therefore, this paper reviews the current clinical studies on traditional Chinese medicine combined with chemotherapy in the treatment of non-small cell lung cancer.
文章引用：阿力木·依明, 马亚丽, 马红霞. 中医药联合化疗在非小细胞肺癌中的研究进展[J]. 临床医学进展, 2023, 13(9): 13857-13862. https://doi.org/10.12677/ACM.2023.1391937

参考文献

[1] 王林, 吴翠芸, 汪贤竹, 等. 黄芩苷对肺癌A549细胞自噬及上皮间质转化的影响[J]. 中国细胞生物学学报, 2020, 42(11): 1960-1968.
[2] 林丽珠, 王思愚, 黄学武. 肺癌中西医结合诊疗专家共识[J]. 中医肿瘤学杂志, 2021, 3(6): 1-17.
[3] 刘宗超, 李哲轩, 张阳, 等. 2020全球癌症统计报告解读[J]. 肿瘤综合治疗电子杂志, 2021, 7(2): 1-13.
[4] Hirsch, F.R., Scagliotti, G.V., Mulshine, J.L., et al. (2017) Lung Cancer: Current Therapies and New Tar-geted Treatments. The Lancet, 389, 299-311. [Google Scholar] [CrossRef] 
[5] Wei, M. and Qiao, Y. (2020) Progress of Lung Cancer Screening with Low Dose Helical Computed Tomography. Chinese Journal of Lung Cancer, 23, 875-882.
[6] González-Marrón, A., et al. (2019) Relation between Tobacco Control Policies and Population at High Risk of Lung Cancer in the European Union. Environmental Research, 179, Article ID: 108594. [Google Scholar] [CrossRef] [PubMed]
[7] Wang, R., et al. (2019) MiR-326/Sp1/KLF3: A Novel Regula-tory Axis in Lung Cancer Progression. Cell Proliferation, 52, e12551. [Google Scholar] [CrossRef] [PubMed]
[8] Khandelwal, A., et al. (2020) Circulating MicroRNA-590-5p Functions as a Liquid Biopsy Marker in Non-Small Cell Lung Cancer. Cancer Science, 111, 826-839. [Google Scholar] [CrossRef] [PubMed]
[9] Mangal, S., Gao, W., Li, T.L. and Zhou, Q. (2017) Pulmonary Delivery of Nanoparticle Chemotherapy for the Treatment of Lung Cancers: Challenges and Opportunities. Acta pharmacologica Sinica, 38, 782-797. [Google Scholar] [CrossRef] [PubMed]
[10] Pirker, R. (2020) Chemotherapy Remains a Cornerstone in the Treatment of Nonsmall Cell Lung Cancer. Current Opinion in Oncology, 32, 63-67. [Google Scholar] [CrossRef] 
[11] Hanna, N., et al. (2017) Systemic Therapy for Stage IV Non-Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update. Journal of Clinical Oncology, 35, 3484-3515. [Google Scholar] [CrossRef] 
[12] Sandler, A., et al. (2006) Paclitaxel-Carboplatin Alone or with Bevacizumab for Non-Small-Cell Lung Cancer. The New England Journal of Medicine, 355, 2542-2550. [Google Scholar] [CrossRef] 
[13] Thatcher, N., et al. (2015) Necitumumab plus Gemcitabine and Cis-platin versus Gemcitabine and Cisplatin Alone as First-Line Therapy in Patients with Stage IV Squamous Non-Small-Cell Lung Cancer (SQUIRE): An Open-Label, Randomised, Controlled Phase 3 Trial. The Lancet Oncology, 16, 763-774. [Google Scholar] [CrossRef] 
[14] Garon, E.B., et al. (2014) Ramucirumab plus Docetaxel ver-sus Placebo plus Docetaxel for Second-Line Treatment of Stage IV Non-Small-Cell Lung Cancer after Disease Progres-sion on Platinum-Based Therapy (REVEL): A Multicentre, Double-Blind, Randomised Phase 3 Trial. The Lancet, 384, 665-673. [Google Scholar] [CrossRef] 
[15] Goldstraw, P., et al. (2016) The IASLC Lung Cancer Staging Project: Proposals for Revision of the TNM Stage Groupings in the Forthcoming (Eighth) Edition of the TNM Classification for Lung Cancer. Journal of Thoracic Oncology, 11, 39-51.
[16] Hirsch, F.R., et al. (2017) Lung Cancer: Current Therapies and New Targeted Treatments. The Lancet, 389, 299-311. [Google Scholar] [CrossRef] 
[17] Kris, M.G., et al. (2017) Adjuvant Systemic Therapy and Adjuvant Radiation Therapy for Stage I to IIIA Completely Resected Non-Small-Cell Lung Cancers: American Society of Clinical Oncology/Cancer Care Ontario Clinical Practice Guideline Update. Journal of Clinical Oncology, 35, 2960-2974. [Google Scholar] [CrossRef] 
[18] Liang, H., et al. (2018) Robotic versus Video-Assisted Lobecto-my/Segmentectomy for Lung Cancer: A Meta-Analysis. Annals of Surgery, 268, 254-259. [Google Scholar] [CrossRef] 
[19] Dillman, R.O., et al. (1990) A Randomized Trial of Induc-tion Chemotherapy plus High-Dose Radiation versus Radiation Alone in Stage III Non-Small-Cell Lung Cancer. The New England Journal of Medicine, 323, 940-945. [Google Scholar] [CrossRef] 
[20] Curran, W.J., et al. (2011) Sequential vs. Concurrent Chemoradiation for Stage III Non-Small Cell Lung Cancer: Randomized Phase III Trial RTOG 9410. Journal of the Na-tional Cancer Institute, 103, 1452-1460. [Google Scholar] [CrossRef] [PubMed]
[21] Herbst, R.S., Heymach, J.V. and Lippman, S.M. (2008) Lung Cancer. The New England Journal of Medicine, 359, 1367-1380. [Google Scholar] [CrossRef] 
[22] Morgensztern, D., Ng, S.H., Gao, F. and Govindan, R. (2010) Trends in Stage Distribution for Patients with Non-Small Cell Lung Cancer: A National Cancer Database Survey. Journal of Thoracic Oncology, 5, 29-33. [Google Scholar] [CrossRef] 
[23] 魏玉磊, 刘腾飞, 韩媛媛, 等. 新辅助化疗联合手术治疗IIIA-N2期非小细胞肺癌临床疗效观察[J]. 山东医药, 2020, 60(21): 61-64.
[24] 王学谦, 侯炜, 郑佳彬, 等. 中医综合治疗方案维持治疗晚期非小细胞肺癌的多中心、大样本、前瞻性队列研究[J]. 中医杂志, 2020, 61(8): 690-694.
[25] 马俊杰, 王小龙, 刘会平. 不同证型非小细胞肺癌患者肿瘤组织代谢组学研究[J]. 中国中西医结合杂志, 2015, 35(6): 659-663.
[26] 刘海涛, 冯解语, 罗斌, 等. 基于数据挖掘田建辉主任医师中医药综合治疗肺癌用药规律研究[J]. 中医研究, 2018, 31(10): 45-49.
[27] 朱赛君, 许尤琪. 中药复方治疗肺癌作用机理的实验研究进展[J]. 中医药导报, 2018, 24(12): 57-61.
[28] 孟晓, 韩燕, 徐咏梅, 等. 中医辨证论治方案维持治疗晚期非小细胞肺癌的临床评价[J]. 中医药导报, 2015, 21(16): 32-36.
[29] 李天传, 陈乃杰, 陈云莺, 张劭琴. 基于临床受益反应评价扶正固本汤辅助治疗晚期肺癌疗效[J]. 实用中医内科杂志, 2021, 35(2): 125-128.
[30] 黄洋, 冯彦, 王作刚, 于亮, 赵子梁. 扶正解毒疏肝化瘀软坚中药内服配合中医理疗治疗肺癌的临床效果观察[J]. 临床医药文献电子杂志, 2019, 6(21): 161-162.
[31] 孙建. 六君二陈汤联合AP方案治疗晚期非小细胞肺癌的临床观察[D]: [硕士学位论文]. 扬州: 扬州大学, 2019.
[32] 孙艾琳. 扶正抑瘤汤治疗气虚血瘀型非小细胞肺癌化疗患者的临床观察[D]: [硕士学位论文]. 哈尔滨: 黑龙江中医药大学, 2019.
[33] 孙玲玲. 益气除痰方维持治疗中晚期非小细胞肺癌的疗效观察及抗转移机制研究[D]: [博士学位论文]. 广州: 广州中医药大学, 2019.
[34] 张振飞. 芪莲合剂治疗气虚血瘀型中晚期NSCLC患者临床疗效及芪莲药对抑制细胞迁移的活性组分筛选[D]: [硕士学位论文]. 济南: 山东中医药大学, 2021.
[35] 任小瑞. 益气消癥方联合化疗治疗晚期非小细胞肺癌患者疗效的回顾性研究[D]: [硕士学位论文]. 广州: 广州中医药大学, 2021.
[36] 刘娟. 中医治疗非小细胞肺癌方药应用文献研究[D]: [硕士学位论文]. 南京: 南京中医药大学, 2020.
[37] 韩茹. 中医维持治疗对晚期NSCLC预后影响的临床研究[D]: [硕士学位论文]. 长春: 长春中医药大学, 2020.

为你推荐